Viewing Study NCT01096732



Ignite Creation Date: 2024-05-05 @ 10:24 PM
Last Modification Date: 2024-10-26 @ 10:18 AM
Study NCT ID: NCT01096732
Status: TERMINATED
Last Update Posted: 2014-01-08
First Post: 2010-03-30

Brief Title: Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma PDAC in the Preoperative Setting HIPPoS
Sponsor: Lisa Bax
Organization: Cambridge University Hospitals NHS Foundation Trust

Study Overview

Official Title: Proof of Mechanism Study of an Oral Hedgehog Inhibitor GDC-0449 in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period
Status: TERMINATED
Status Verified Date: 2014-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Slow recruitment
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: HIPPoS
Brief Summary: This clinical trial is looking at the effect of a new drug called GDC-0449 in patients with cancer of the pancreas Laboratory studies have shown that this drug blocks a process in pancreatic cells thought to be involved in cancer development and spread This process is called the Hedgehog signalling pathway As yet it is unclear whether blocking hedgehog signalling will directly affect the tumour cells themselves or the surrounding normal tissue Understanding this distinction will help improve treatment strategies for pancreatic cancer Patients will be offered to participate in this research study if they have localised pancreatic cancer that can be removed by surgery In the period between diagnosis and surgery the investigators do not normally treat patients however in this trial the investigators will ask patients to take GDC-0449 during the approximately two weeks until the day of surgery All patients that enter this study will have undergone a diagnostic biopsy of the pancreatic tumour and the investigators will collect a second sample of the tumour at surgery The main question of this study is whether the investigators can detect a change in hedgehog signalling in the normal tumour surrounding tissue Furthermore the investigators will look very carefully whether this treatment is safe for patients All problems before and after surgery will be carefully documented and the investigators have defined strict rules to stop the study if the investigators observe serious problems
Detailed Description: Please contact Principal Investigators team for full details

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None